TY - JOUR
KW - Administration, Inhalation
KW - Adrenal Cortex Hormones
KW - Adrenergic beta-2 Receptor Agonists/adverse effects
KW - *Asthma/drug therapy
KW - Beclomethasone/therapeutic use
KW - Budesonide, Formoterol Fumarate Drug Combination/therapeutic use
KW - Formoterol Fumarate/therapeutic use
KW - Humans
KW - Muscarinic Antagonists/therapeutic use
KW - Primary health care
KW - *Pulmonary Disease, Chronic Obstructive/drug therapy
KW - Retrospective Studies
KW - COPD epidemiology
KW - COPD pharmacology
KW - inhaler devices
AU - A. Czira
AU - V. Banks
AU - G. Requena
AU - R. Wood
AU - T. Tritton
AU - R. Wild
AU - C. Compton
AU - M. Duarte
AU - A. Ismaila
AD - Value Evidence and Outcomes, GSK, R&D Global Medical, Brentford, Middlesex, UK Alexandrosz.x.czira@gsk.com.
Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK.
Value Evidence and Outcomes, GSK, R&D Global Medical, Brentford, Middlesex, UK.
Value Evidence and Outcomes, GSK, Collegeville, Pennsylvania, USA.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
AN - 36171051
BT - BMJ Open Respir Res
C2 - PMC9528685
DO - 10.1136/bmjresp-2022-001243
DP - NLM
ET - 2022/09/29
LA - eng
M1 - 1
N1 - 2052-4439
Czira, Alexandrosz
Banks, Victoria
Requena, Gema
Wood, Robert
Tritton, Theo
Wild, Rosie
Compton, Chris
Duarte, Maria
Ismaila, Afisi S
Journal Article
Research Support, Non-U.S. Gov't
BMJ Open Respir Res. 2022 Sep;9(1):e001243. doi: 10.1136/bmjresp-2022-001243.
PY - 2022
SN - 2052-4439
T2 - BMJ Open Respir Res
TI - Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England
VL - 9
ER -